Plain-English translation of NCT06793553 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment strategy for advanced triple-negative breast cancer using paclitaxel and bevacizumab. The study compares two approaches: one group receives two cycles of these drugs first, then switches to atezolizumab combined with nab-paclitaxel; the other group receives the immunotherapy combination right away. Researchers believe that starting with the initial chemotherapy may prepare the body's immune system to respond better to the later immunotherapy.
Current standard treatment for this aggressive form of breast cancer works, but it doesn't help everyone equally or for very long. This trial explores whether a two-step approach—priming the immune system first—might help the medication work better and keep the cancer from progressing longer.
You likely qualify if…
You likely don't qualify if…
If you join the induction group, you will receive two cycles of chemotherapy (paclitaxel and bevacizumab) followed by cycles of immunotherapy combined with a different chemotherapy (atezolizumab and nab-paclitaxel). If you join the standard group, you will receive the immunotherapy combination right away. You will have regular clinic visits for treatment, blood tests, and imaging scans to monitor how well the treatment is working. The trial will track how long your cancer stays under control and collect tissue and blood samples to understand how the treatment affects your immune system.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Japan
Phase
Testing effectiveness
Sponsor
Japan Breast Cancer Research Group
Collaborators
Chugai Pharmaceutical
Enrollment target
~106 participants
Started
September 2024
Primary completion
March 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yukinori Ozaki
Japan Breast Cancer Research Group
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.